TREM-1

TREM-1 Informations sur la molécule

Nom anglais	Triggering receptor expressed on myeloid cells 1	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	6	Alias de la cible	Triggering Receptor Expressed On Myeloid Cells 1，CD354 Antigen，Triggering Receptor Expressed on Myeloid Cells-1，TREM-1，TREM1，CD354，Triggering receptor expressed on monocytes 1
Phase de R&D la plus avancée	Phase 2 Clinical

Nom anglais	Triggering receptor expressed on myeloid cells 1
Alias de la cible	Triggering Receptor Expressed On Myeloid Cells 1，CD354 Antigen，Triggering Receptor Expressed on Myeloid Cells-1，TREM-1，TREM1，CD354，Triggering receptor expressed on monocytes 1
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	6
Phase de R&D la plus avancée	Phase 2 Clinical

TREM-1 Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
Fc Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
AIDD‑Ready TR1-H5251	Human	HEK293	Human TREM-1 / CD354 Protein, Fc Tag, low endotoxin				Ajouter au panier

Quantité totale1

Demande de produit

TREM-1Contexte de la molécule

Triggering receptor expressed on myeloid cells 1 (TREM1) is also known as CD antigen CD354, and is a type I transmembrane protein with a single Ig-like domain. TREM1 is highly expressed in adult liver, lung and spleen than in corresponding fetal tissue. TREM-1 / CD354 stimulates neutrophil and monocyte-mediated inflammatory responses, and also triggers release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers. Amplifier of inflammatory responses that are triggered by bacterial and fungal infections and is a crucial mediator of septic shock. TREM1 can interacts with TYROBP / DAP12.

TREM-1Alias de la molécule

TREM1,CD354

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Nangibotide	LR-12	Phase 2 Clinical	Inotrem	Coronavirus Disease 2019 (COVID-19); Shock, Septic	Details
ABBV-8736	ABBV-8736	Phase 2 Clinical	Abbvie Inc	Crohn Disease; Inflammatory Bowel Diseases	Details
TREM-1 antibody (Boehringer Ingelheim)		Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Autoimmune Diseases	Details
CEL383	CEL-383	Phase 1 Clinical	Celsius Therapeutics Inc	Inflammatory Bowel Diseases	Details
TREM 1 antibody(Boehringer Ingelheim International Gmbh)	TREM 1 antibody(Boehringer Ingelheim International Gmbh)	Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Immune System Diseases	Details
PY-159	PY-159	Phase 1 Clinical	Centre for the Commercialization of Antibodies and Biologics	Neoplasms; Solid tumours	Details